Business
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026.\n \n \n \n \n \n \n \nThese studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing precision oncology through deep molecular interrogation. The studies focused on breast, prostate, lung and colorectal cancers represent a collaborative effort between Caris and leading cancer centers and institutions, underscoring the power of large‑scale, real world molecular evidence to accelerate discovery and improve patient outcomes.\"These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden,\" said James Hamrick, MD, MPH, Chairman of the Caris POA. \"By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients.\"Posters Include:Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancerSession: Spatial Proteomics and Transcriptomics 1 Sunday, April 19, 2026, 2:00 PM – 5:00 PM PSTPoster #: 1200/1 Location: Poster section 47Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLCSession: Biomarkers Predictive of Therapeutic Benefit 3Monday, April 20, 2026, 9:00 AM – 12:00 PM PSTPoster #: 2434/4Location: Poster section 40AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resis...